ITD is a driver mutation that
accelerates disease progression
in FLT3-ITD+ AML

Learn about FLT3-ITD mutations in AML and the importance of FLT3-ITD testing.

AML is a difficult disease made more challenging with the FLT3-ITD mutation1

AML is a malignant disease that results from the abnormal proliferation and differentiation of myeloid stem cells in the bone marrow. AML is one of the most common forms of leukemia in adults, representing about 80% of all cases.2

In AML, there are many mutations, but the most common is the FLT3 mutation, which includes ITD and TKD.3

AML with FLT3-ITD mutations (without adverse-risk genetic lesions) is categorized as intermediate-risk and is associated with poor prognosis.4

FLT3-ITD mutations activate FLT3 kinase activity, resulting in proliferation and survival of myeloblasts in AML1

FLT3-ITD+ AML often has a poorer prognosis compared to FLT3-TKD+ AML,
and ITD is a driver mutation with a higher leukemic burden.1

FLT3-ITD is one of the most prevalent and aggressive mutations in AML3

FLT3-ITD+ AML patients are

3.5x
less likely to survive compared to patients with a FLT3-TKD mutation5,6 *

80%
of all FLT3 mutations are ITD, making up ~30% of all AML cases3

Until now, there has not been a treatment that targets only the FLT3-ITD+
mutation for patients with newly diagnosed FLT3-ITD+ AML.7-9

Recognize the risk. Test for ITD mutations.
Act now with a targeted FLT3-ITD inhibitor.

*Studied comparing 5-year survival rates of patients with TKD mutations (53% OS) vs patients with ITD mutations (15% OS).5,6

The importance of testing for FLT3-ITD mutations

FLT3-ITD+ adversely impacts outcomes in patients with AML1

down arrow icon
Shorter overall survival10
Shorter overall survival10
up arrow icon
Increased risk of relapse10
Increased risk of relapse10

Of all the patients with FLT3-ITD+ AML at the time of diagnosis, 75% continue to have the ITD mutation at relapse, suggesting that FLT3-ITD may be responsible for disease progression.1

Testing all patients with AML for FLT3-ITD mutations quickly may lead to improved care1

An FDA-approved clinical study assay such as LeukoStrat® CDx FLT3 Mutation Assay
is a direct way to identify FLT3-ITD mutations.4,11

LeukoStrat® CDx FLT3 Mutation Assay has a turnaround time of 2-3 business days.12

genetic mutation icon
Recognize the risk. Know their ITD status. Learn what’s driving FLT3 in your patients with AML and act now with a targeted FLT3-ITD+ inhibitor.
References:

1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299-312. doi:10.1038/s41375-018-0357-9 2. Vakiti A, Mewawalla P. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK507875. Accessed December 15, 2023. 3. Patel PJ, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089. doi:10.1056/NEJMoa1112304 4. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2023 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. doi:10.1182/blood.2022016867 5. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784. doi:10.1182/blood-2007-08-109090 6. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110(4):1262-1270. doi:10.1182/blood-2006-04-015826 7. VANFLYTA [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2023. 8. XOSPATA [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2023. 9. RYDAPT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. 10. Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Published online: April 25, 2023. doi:10.1016/S0140-6736(23)00464-6 11. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP 12. LeukoStrat CDx FLT3 Mutation Assay. San Diego, CA: Invivoscribe, Inc; 2017. Accessed August 31, 2023. https://invivoscribe.com/uploads/products/informationalDownloads/LabPMM-Flyer_Leukostrat-CDx_FLT3_8.5x11_20170420.pdf